Carderock Capital Management’s Novartis NVS Stock Holding History

Carderock Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-175	Closed	-$16.1K	–	102
2023 Q1	$16.1K	Buy	+175	New	+$15.3K	0.01%	118
2016 Q3	–	Sell	-13,450	Closed	-$994K	–	80
2016 Q2	$994K	Sell	13,450 -3,374	-20%	-$233K	0.53%	55
2016 Q1	$1.09M	Sell	16,824 -37,842	-69%	-$2.57M	0.56%	52
2015 Q4	$4.21M	Sell	54,666 -111	-0.2%	-$8.82K	2.19%	19
2015 Q3	$4.51M	Buy	54,777 +222	+0.4%	+$19.8K	2.52%	11
2015 Q2	$4.81M	Buy	54,555 +80	+0.1%	+$7.34K	2.41%	13
2015 Q1	$4.81M	Sell	54,475 -125	-0.2%	-$11.1K	2.33%	13
2014 Q4	$4.53M	Sell	54,600 -97	-0.2%	-$8.04K	2.23%	16
2014 Q3	$4.61M	Buy	54,697 +21,829	+66%	+$1.77M	2.37%	8
2014 Q2	$2.67M	Buy	32,868 +938	+3%	+$73.8K	1.39%	28
2014 Q1	$2.43M	Buy	31,930 +325	+1%	+$23.7K	1.24%	33
2013 Q4	$2.28M	Buy	+31,605	New	+$2.2M	1.19%	36

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Carderock Capital Management's NVS Position: Q2 2023 in Review

Carderock Capital Management sold out of Novartis (NVS) in Q2 2023, closing a stake of 175 shares — an estimated $16.1K sold.

Carderock Capital Management first reported a position in NVS in Q4 2013 and held it in 12 quarters. The position peaked at $4.81M in Q1 2015. 1,203 funds tracked by Wall St. Rank hold NVS as of Q2 2023.

Carderock Capital Management reported no remaining Novartis position as of Q2 2023 after selling out during the quarter.
Carderock Capital Management sold 175 Novartis shares in Q2 2023, an estimated $16.1K.
Carderock Capital Management first reported a position in Novartis in Q4 2013 and held it in 12 quarters.
Carderock Capital Management's Novartis position peaked at $4.81M in Q1 2015.
1,203 funds tracked by Wall St. Rank held Novartis as of Q2 2023.

Based on Carderock Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.